MA40846A - COMPOSITIONS OF FATTY ACIDS AND SELF-MICELLIZING FATTY ACID ESTERS, AS WELL AS THEIR USE IN THE TREATMENT OF DISEASE CONDITIONS - Google Patents

COMPOSITIONS OF FATTY ACIDS AND SELF-MICELLIZING FATTY ACID ESTERS, AS WELL AS THEIR USE IN THE TREATMENT OF DISEASE CONDITIONS

Info

Publication number
MA40846A
MA40846A MA040846A MA40846A MA40846A MA 40846 A MA40846 A MA 40846A MA 040846 A MA040846 A MA 040846A MA 40846 A MA40846 A MA 40846A MA 40846 A MA40846 A MA 40846A
Authority
MA
Morocco
Prior art keywords
micellizing
compositions
self
treatment
well
Prior art date
Application number
MA040846A
Other languages
French (fr)
Inventor
Ahmed Abd Almalik Ahmed Mohammed Daak
Glynis Daniel-Archibald
Miguel Lopez-Toledano
Frederick D Sancilio
Thorsteinn Thorsteinsson
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40846(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of MA40846A publication Critical patent/MA40846A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
MA040846A 2014-10-10 2015-10-08 COMPOSITIONS OF FATTY ACIDS AND SELF-MICELLIZING FATTY ACID ESTERS, AS WELL AS THEIR USE IN THE TREATMENT OF DISEASE CONDITIONS MA40846A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462062638P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
MA40846A true MA40846A (en) 2017-09-05

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040846A MA40846A (en) 2014-10-10 2015-10-08 COMPOSITIONS OF FATTY ACIDS AND SELF-MICELLIZING FATTY ACID ESTERS, AS WELL AS THEIR USE IN THE TREATMENT OF DISEASE CONDITIONS

Country Status (8)

Country Link
EP (1) EP3212236A1 (en)
BR (1) BR112017007428A2 (en)
CA (1) CA2963952C (en)
CL (1) CL2017000867A1 (en)
MA (1) MA40846A (en)
MX (2) MX2017004324A (en)
WO (1) WO2016057915A1 (en)
ZA (1) ZA201702385B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017193563A1 (en) * 2015-11-13 2017-11-16 深圳君圣泰生物技术有限公司 Composition, and application and pharmaceutical preparation thereof
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 Pharmaceutical compositions and applications thereof, and pharmaceutical preparation
AU2017301077B2 (en) * 2016-08-12 2022-07-07 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
FR3092968B1 (en) * 2019-02-22 2021-05-21 Microphyt DIETARY SUPPLEMENT
IT201900007202A1 (en) * 2019-05-24 2020-11-24 Pavia Farm S R L COMPOSITION BASED ON LIPOSOLUBLE VITAMINS WITH HIGH ENTERIC ABSORPTION
WO2021028737A1 (en) 2019-08-13 2021-02-18 Team Foods Colombia S.A. Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of non-alcoholic fatty liver disease (nafld)
CN115737555A (en) * 2022-05-20 2023-03-07 深圳海王医药科技研究院有限公司 Cepharanthine self-microemulsion composition, preparation and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010134614A1 (en) * 2009-05-22 2010-11-25 持田製薬株式会社 SELF-EMULSIFYING COMPOSITION OF ω3 FATTY ACID
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
MY189576A (en) * 2012-03-30 2022-02-17 Micelle Biopharma Inc Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
CA2963952A1 (en) 2016-04-14
MX2017004324A (en) 2017-07-04
BR112017007428A2 (en) 2017-12-19
EP3212236A1 (en) 2017-09-06
MX2020002238A (en) 2020-07-13
ZA201702385B (en) 2020-12-23
CL2017000867A1 (en) 2017-11-03
WO2016057915A1 (en) 2016-04-14
CA2963952C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
MA40846A (en) COMPOSITIONS OF FATTY ACIDS AND SELF-MICELLIZING FATTY ACID ESTERS, AS WELL AS THEIR USE IN THE TREATMENT OF DISEASE CONDITIONS
FR23C1010I2 (en) BISPECIFIC ANTI-ANG-2/ANTI-VEGF ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
FR23C1035I1 (en) PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE TO TREAT PARKINSON’S DISEASE
EP3349783C0 (en) Compositions and methods relating to the treatment of diseases
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
MA39960A (en) IMIDAZO [4,5C] QUINOLINE-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
NZ757815A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
BR112018005905A2 (en) ? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
CY1123942T1 (en) OMEGA-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISEASES CAUSING DAMAGE TO THE NERVOUS SYSTEM
EP3661600A4 (en) Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
CL2014003325A1 (en) Compounds derived from difluoro-hexahydro-cyclopentaoxacinyls and difluoro-hexahydro-benzooxacinyls, bace 1 inhibitors; pharmaceutical composition; and its use in the treatment of diseases with elevated levels of beta-amyloid, such as Alzheimer's disease
BR112016020181A2 (en) LIPOIC ACID ESTER CHOLINE COMPOSITIONS AND METHODS OF USE.
FR3030231B1 (en) USE OF A FATTY ACID ESTER FOR MATIFYING THE SKIN AND COMPOSITION COMPRISING SAID ESTER
MX2015017457A (en) Use of a composition comprising fish oil and juice for the treatment of inflammation.
MA52644A (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF DGLA ACID AND THEIR USE
PL2892556T3 (en) Compositions and methods relating to the treatment of diseases
EP3318261A4 (en) Use of zoledronic acid to prepare drug treating fatty liver disease
FR2990945B1 (en) NOVEL STRIGOLACTONE ANALOGUES AND THEIR USE FOR PLANT TREATMENT
MX2017001293A (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders.
MA39912B1 (en) Derivatives of 2-aryl-4-hydroxy-1,3-thiazole as trpm8 antagonists, and their use in the treatment of neuralgia, pain, bpco and asthma.
MX370990B (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
HK1219063A1 (en) Pharmaceutical compositions containing hyaluronic acid for use in the treatment of black disk disease
EP3027180A4 (en) Compositions and methods of the treatment of fatty acid metabolism disorders
WO2015031198A3 (en) Bendamustine pharmaceutical compositions
FR3012329B1 (en) ASSOCIATION VITAMIN C AND HYALURONIC ACID FOR THE TREATMENT OF THE EFFECTS OF SKIN AGING.